News - Zytiga, BTG

Filter

Current filters:

ZytigaBTG

Popular Filters

1 to 25 of 49 results

BTG’s varicose vein treatment Varithena gets FDA approval

BTG’s varicose vein treatment Varithena gets FDA approval

27-11-2013

UK specialist health care company BTG (LSE: BTG) has received approval from the US Food and Drug Administration…

BTGPharmaceuticalRegulationUKUSAVarithena

BTG reveals six-month revenue up 17% and meets analysts’ expectations

12-11-2013

UK specialist health care company BTG (LSE: BTG) has announced its interim results for the six months…

BTGEuropeFinancialLemtradaOncologyPharmaceuticalTheraSphereUKZytiga

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

11-10-2013

Anglo-Swedish drug major AstraZeneca has entered into an agreement with US health care giant Johnson…

abirateroneAsia-PacificAstraZenecaJanssenJohnson & JohnsonLicensingMarkets & MarketingOncologyPharmaceuticalZytiga

BTG ups full year guidance following acquisitions

03-10-2013

UK specialist health care company BTG has provided an update for the six months ended September 30, 2013,…

BTGFinancialMergers & AcquisitionsPharmaceutical

UK's BTG sells brachytherapy business for $5million

UK's BTG sells brachytherapy business for $5million

17-09-2013

UK-based specialty pharma company BTG (LSE: BTG) has sold its brachytherapy business to German company…

BTGEuropeMergers & AcquisitionsPharmaceutical

Prostate cancer market set to grow 50% by 2021: report

06-09-2013

The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

UK's NICE recommends new therapy for liver cancer patients

30-07-2013

UK specialist health care company BTG (LSE: BTG) says that the UK's National Institute for Health and…

BiotechnologyBTGEuropeNephrology and HepatologyNordionOncologyRegulation

Nordion to sell Targeted Therapies business to BTG for $200 million

24-05-2013

Canada's Nordion (TSX: NDN), a provider of products and services for the prevention, diagnosis and treatment…

BTGMergers & AcquisitionsNordionOncologyPharmaceuticalTargeted TherapiesTheraSphere

Six months post launch, US prescribing trends for Xtandi

07-05-2013

At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

IQWiG says some men with metastatic prostate cancer can benefit from J&J's Zytiga

29-04-2013

In an early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products…

EuropeJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

US FDA accepts NDAs for Otsuka's tolvaptan and BTG's Varisolve

12-04-2013

Japanese mid-sized drugmaker Otsuka Pharmaceutical (TYO: 4578) says that the US Food and Drug Administration…

BTGCardio-vascularNephrology and HepatologyNorth AmericaOtsukaPharmaceuticalRare diseasesRegulationtolvaptanVarisolve

Study shows additional role for abiraterone in blocking tumor growth in CRPC

17-03-2013

As part of a European Union-supported IMI-PREDECT consortium (http://www.predect.eu), a Dutch study showed…

abirateroneJanssenJohnson & JohnsonOncologyPharmaceuticalResearchZytiga

Expanded indication for Janssen's Zytiga cleared in EU

14-01-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International said Friday…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationZytiga

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Prostate cancer drug market will more than double to $9.1 billion in 2021

06-11-2012

The prostate cancer drug market will more than double, increasing from $4.1 billion in 2011 to $9.1 billion…

Astellas PharmaGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalXtandiZytiga

ESMO 2012 Congress highlights

01-10-2012

The European Society for Medical Oncology (ESMO) Congress kicked off in Vienna, Austria, last Friday…

GlaxoSmithKlineJanssenJohnson & JohnsonOncologyPazopanib TabletsPfizerPharmaceuticalResearchXalkoriZytiga

FDA OKs new indication for Janssen's Nucynta and fast tracks Zytiga sNDA

30-08-2012

There were two pieces of good news for US health care giant Johnson & Johnson (NYSE: JNJ) subsidiaries…

BiotechnologyJanssenJohnson & JohnsonNeurologicalNorth AmericaNucyntaOncologyPharmaceuticalRegulationZytiga

1 to 25 of 49 results

Back to top